



## Vaccines against Hepatitis Viruses

Guest Editor:

**Dr. Dirk Wohlleber**  
Institute of Molecular  
Immunology, Technical  
University of Munich, 80333  
Munich, Germany

Deadline for manuscript  
submissions:

**closed (31 March 2021)**

### Message from the Guest Editor

Dear Colleagues,

Hepatitis viruses cause substantial morbidity and mortality worldwide. Immune therapy in the form of vaccination is considered the best option to prevent infection and the sequelae of chronic viral hepatitis, i.e., liver cirrhosis and liver cell cancer. Despite a prophylactic vaccination against Hepatitis B that efficiently protects against infection, numbers of patients with chronic hepatitis B did not decline over the last 10 years and more than 800,000 patients die from the consequences of chronic hepatitis every year. A therapeutic vaccination is therefore needed because no curative anti-viral treatment is available so far.

This issue focuses on the current research towards immunity against viral infections of the liver. Understanding the interaction of local immune cells in the liver with hepatocytes and non-parenchymal liver cells may be crucial in developing translational approaches to establish treatment strategies to overcome chronic viral hepatitis.

Dr. Dirk Wohlleber  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)